ALLERGY Journal
Overview
publication venue for
- Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials 2021
- From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases 2021
- Efficacy and safety of benralizumab for the treatment of chronic rhinosinusitis with nasal polyps: results from the phase III OSTRO trial 2021
- Dupilumab rapidly improves sense of smell in patients with severe chronic rhinosinusitis with nasal polyps: Pooled results from the SINUS-24 and SINUS-52 phase 3 studies 2020
- Omalizumab is associated with a reduced need for surgery in patients with nasal polyposis 2020
- Baseline characteristics of phase 3 randomized controlled trials of omalizumab in chronic rhinosinusitis with nasal polyps 2019
- Dupilumab reduces need for systemic corticosteroid use, sinonasal surgery in patients with severe chronic rhinosinusitis with nasal polyps: Pooled results from the SINUS-24, SINUS-52 phase 3 studies 2019
- EUFOREA consensus on biologics for CRSwNP with or without asthma 2019
Identity
International Standard Serial Number (ISSN)
- 0105-4538
Electronic International Standard Serial Number (EISSN)
- 1398-9995